Awuson-David Betina, Williams Adrian C, Wright Benjamin, Hill Lisa J, Di Pietro Valentina
School of Biomedical Sciences, Institute of Clinical Sciences, University of Birmingham, Birmingham, United Kingdom.
Department of Neurology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Front Neurosci. 2023 Sep 1;17:1228927. doi: 10.3389/fnins.2023.1228927. eCollection 2023.
MicroRNAs (miRNAs) are small non-coding RNAs involved in gene regulation. Recently, miRNA dysregulation has been found in neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The diagnosis of Alzheimer's and Parkinson's is currently challenging, mainly occurring when pathology is already present, and although treatments are available for both diseases, the role of treatment is primarily to prevent or delay the progress of the diseases instead of fully overcoming the diseases. Therefore, the challenge in the near future will be to determine effective drugs to tackle the dysregulated biological pathways in neurodegenerative diseases. In the present study, we describe the dysregulation of miRNAs in blood of Alzheimer's and Parkinson's patients with the aim to identify common mechanisms between the 2 pathologies and potentially to identify common therapeutic targets which can stop or delay the progression of two most frequent neuropathologies. Two independent systematic reviews, bioinformatic analysis, and experiment validation were performed to identify whether AD and PD share common pathways. A total of 15 common miRNAs were found in the literature and 13 common KEGG pathways. Among the common miRNAs, two were selected for validation in a small cohort of AD and PD patients. Let-7f-5p and miR-29b-3p showed to be good predictors in blood of PD patients.
微小RNA(miRNA)是参与基因调控的小非编码RNA。最近,在阿尔茨海默病(AD)和帕金森病(PD)等神经退行性疾病中发现了miRNA失调。目前,阿尔茨海默病和帕金森病的诊断具有挑战性,主要在病理状态已经出现时才得以诊断,并且尽管这两种疾病都有相应治疗方法,但治疗的作用主要是预防或延缓疾病进展,而非完全攻克这些疾病。因此,在不久的将来,挑战将是确定有效的药物来应对神经退行性疾病中失调的生物学途径。在本研究中,我们描述了AD和PD患者血液中miRNA的失调情况,目的是确定这两种病理状态之间的共同机制,并潜在地确定可以阻止或延缓两种最常见神经病理学进展的共同治疗靶点。我们进行了两项独立的系统评价、生物信息学分析和实验验证,以确定AD和PD是否共享共同途径。在文献中总共发现了15种共同的miRNA和13条共同的KEGG途径。在这些共同的miRNA中,选择了两种在一小群AD和PD患者中进行验证。Let-7f-5p和miR-29b-3p在PD患者血液中显示出是良好的预测指标。